PHARA METELLUS: Open Payments
NPI 1851843403 · LAKE WORTH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,092 in 51 payments from 11 companies in 2025. Trend: 2023 $117 · 2024 $447 · 2025 $1,092
Food & beverage: $1,092
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $241 |
| Alkermes, Inc. | 9 | $190 |
| Neurocrine BioSciences, Inc. | 7 | $138 |
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| Janssen Pharmaceuticals, Inc | 4 | $121 |
| E.R. Squibb & Sons, L.L.C. | 4 | $106 |
| ABBVIE INC. | 3 | $62 |
| Lundbeck LLC | 2 | $39 |
| Corium, LLC | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: CAPLYTA, ARISTADA, INGREZZA, INVEGA SUSTENNA, COBENFY, UZEDY, VRAYLAR, REXULTI.
Industry payments across FL — which companies pay providers there.
